Monoclonal Antibodies for Chronic Pain Treatment: Present and Future

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Oct 13

PMID 34638667

Citations 11

Authors

Eva M Sanchez-Robles

Rocio Giron

Nancy Paniagua

Carmen Rodriguez-Rivera

David Pascual

Carlos Goicoechea

Affiliations

Soon will be listed here.

Abstract

Chronic pain remains a major problem worldwide, despite the availability of various non-pharmacological and pharmacological treatment options. Therefore, new analgesics with novel mechanisms of action are needed. Monoclonal antibodies (mAbs) are directed against specific, targeted molecules involved in pain signaling and processing pathways that look to be very effective and promising as a novel therapy in pain management. Thus, there are mAbs against tumor necrosis factor (TNF), nerve growth factor (NGF), calcitonin gene-related peptide (CGRP), or interleukin-6 (IL-6), among others, which are already recommended in the treatment of chronic pain conditions such as osteoarthritis, chronic lower back pain, migraine, or rheumatoid arthritis that are under preclinical research. This narrative review summarizes the preclinical and clinical evidence supporting the use of these agents in the treatment of chronic pain.

Citing Articles

Challenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review.

Doring S, Weller M, Reinders Y, Konthur Z, Jaeger C Antibodies (Basel). 2025; 14(1.

PMID: 39846611 PMC: 11755444. DOI: 10.3390/antib14010003.

Biomolecular therapies for chronic discogenic low back pain: A narrative review.

Rudnik-Jansen I, van Kruining Kodele S, Creemers L, Joosten B JOR Spine. 2024; 7(3):e1345.

PMID: 39114580 PMC: 11303450. DOI: 10.1002/jsp2.1345.

A role of NLRP3 and MMP9 in migraine progression: a systematic review of translational study.

Rushendran R, Singh A, Singh S, Chitra V, Ilango K Front Neurol. 2024; 15:1307319.

PMID: 38836002 PMC: 11148868. DOI: 10.3389/fneur.2024.1307319.

Recent Advances in Management of Neuropathic, Nociceptive, and Chronic Pain: A Narrative Review with Focus on Nanomedicine, Gene Therapy, Stem Cell Therapy, and Newer Therapeutic Options.

Kataria S, Patel U, Yabut K, Patel J, Patel R, Patel S Curr Pain Headache Rep. 2024; 28(5):321-333.

PMID: 38386244 PMC: 11126447. DOI: 10.1007/s11916-024-01227-5.

The Effect of Group Training or Spinal Orthosis on Quality of Life and Potential Plasma Markers of Pain in Older Women With Osteoporosis. A Randomized Controlled Trial.

Uzunel E, Grahn Kronhed A, Alin C, Ahmed A, Wandell P, Salminen H Arch Rehabil Res Clin Transl. 2024; 5(4):100297.

PMID: 38163036 PMC: 10757196. DOI: 10.1016/j.arrct.2023.100297.

References

Fonseca J, Santos M, Canhao H, Choy E . Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev. 2009; 8(7):538-42. DOI: 10.1016/j.autrev.2009.01.012. View

Ashraf S, Mapp P, Burston J, Bennett A, Chapman V, Walsh D . Augmented pain behavioural responses to intra-articular injection of nerve growth factor in two animal models of osteoarthritis. Ann Rheum Dis. 2013; 73(9):1710-8. PMC: 4145450. DOI: 10.1136/annrheumdis-2013-203416. View

Buss N, Henderson S, McFarlane M, Shenton J, de Haan L . Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol. 2012; 12(5):615-22. DOI: 10.1016/j.coph.2012.08.001. View

Parray H, Shukla S, Samal S, Shrivastava T, Ahmed S, Sharma C . Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharmacol. 2020; 85:106639. PMC: 7255167. DOI: 10.1016/j.intimp.2020.106639. View

Tepper S, Ashina M, Reuter U, Brandes J, Dolezil D, Silberstein S . Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia. 2020; 40(6):543-553. DOI: 10.1177/0333102420912726. View

Strand V, Kosinski M, Chen C, Joseph G, Rendas-Baum R, Graham N . Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016; 18:198. PMC: 5012017. DOI: 10.1186/s13075-016-1096-9. View

Wattiez A, Wang M, Russo A . CGRP in Animal Models of Migraine. Handb Exp Pharmacol. 2019; 255:85-107. PMC: 7008000. DOI: 10.1007/164_2018_187. View

Shibasaki M, Sasaki M, Miura M, Mizukoshi K, Ueno H, Hashimoto S . Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury. Pain. 2010; 149(3):514-521. DOI: 10.1016/j.pain.2010.03.023. View

McNamee K, Burleigh A, Gompels L, Feldmann M, Allen S, Williams R . Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain. 2010; 149(2):386-392. DOI: 10.1016/j.pain.2010.03.002. View

10.

Bayer V . An Overview of Monoclonal Antibodies. Semin Oncol Nurs. 2019; 35(5):150927. DOI: 10.1016/j.soncn.2019.08.006. View

11.

Koninckx P, Craessaerts M, Timmerman D, Cornillie F, Kennedy S . Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod. 2008; 23(9):2017-23. PMC: 2517154. DOI: 10.1093/humrep/den177. View

12.

Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z . Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010; 62(4):917-28. DOI: 10.1002/art.27348. View

13.

Wild K, Bian D, Zhu D, Davis J, Bannon A, Zhang T . Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance. J Pharmacol Exp Ther. 2007; 322(1):282-7. DOI: 10.1124/jpet.106.116236. View

14.

Gwak Y, Nam T, Paik K, Hulsebosch C, Leem J . Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat. Neurosci Lett. 2002; 336(2):117-20. DOI: 10.1016/s0304-3940(02)01251-x. View

15.

Edelmayer R, Brederson J, Jarvis M, Bitner R . Biochemical and pharmacological assessment of MAP-kinase signaling along pain pathways in experimental rodent models: a potential tool for the discovery of novel antinociceptive therapeutics. Biochem Pharmacol. 2013; 87(3):390-8. DOI: 10.1016/j.bcp.2013.11.019. View

16.

Mai L, Zhu X, Huang F, He H, Fan W . p38 mitogen-activated protein kinase and pain. Life Sci. 2020; 256:117885. DOI: 10.1016/j.lfs.2020.117885. View

17.

Mayorga A, Wang S, Kelly K, Thipphawong J . Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. Int J Clin Pract. 2016; 70(6):493-505. DOI: 10.1111/ijcp.12807. View

18.

Bramson C, Herrmann D, Carey W, Keller D, Brown M, West C . Exploring the role of tanezumab as a novel treatment for the relief of neuropathic pain. Pain Med. 2015; 16(6):1163-76. DOI: 10.1111/pme.12677. View

19.

Almeida C, Choy E, Hewlett S, Kirwan J, Cramp F, Chalder T . Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016; (6):CD008334. PMC: 7175833. DOI: 10.1002/14651858.CD008334.pub2. View

20.

Kochi T, Nakamura Y, Ma S, Hisaoka-Nakashima K, Wang D, Liu K . Pretreatment with High Mobility Group Box-1 Monoclonal Antibody Prevents the Onset of Trigeminal Neuropathy in Mice with a Distal Infraorbital Nerve Chronic Constriction Injury. Molecules. 2021; 26(7). PMC: 8038245. DOI: 10.3390/molecules26072035. View